Ascendis Pharma A/S (ASND) Competitors $194.62 -0.96 (-0.49%) Closing price 04:00 PM EasternExtended Trading$194.50 -0.12 (-0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASND vs. TAK, ARGX, ONC, INSM, BNTX, TEVA, SMMT, GMAB, VTRS, and RDYShould you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Ascendis Pharma A/S vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S (NASDAQ:ASND) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Do institutionals & insiders hold more shares of ASND or TAK? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, ASND or TAK? Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Do analysts rate ASND or TAK? Ascendis Pharma A/S presently has a consensus price target of $244.36, suggesting a potential upside of 25.56%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00Takeda Pharmaceutical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer ASND or TAK? In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 10 articles in the media. Ascendis Pharma A/S's average media sentiment score of 1.27 beat Takeda Pharmaceutical's score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ASND or TAK? Takeda Pharmaceutical has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$490.75M24.28-$409.12M-$5.16-37.72Takeda Pharmaceutical$30.09B1.59$712.33M$0.3050.27 Is ASND or TAK more profitable? Takeda Pharmaceutical has a net margin of 3.20% compared to Ascendis Pharma A/S's net margin of -54.94%. Takeda Pharmaceutical's return on equity of 10.50% beat Ascendis Pharma A/S's return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Takeda Pharmaceutical 3.20%10.50%5.10% SummaryTakeda Pharmaceutical beats Ascendis Pharma A/S on 8 of the 15 factors compared between the two stocks. Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASND vs. The Competition Export to ExcelMetricAscendis Pharma A/SMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.91B$3.11B$5.75B$10.28BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-37.7221.3674.9926.41Price / Sales24.28240.89456.1088.49Price / CashN/A44.4425.8129.91Price / Book-103.529.6413.256.28Net Income-$409.12M-$53.20M$3.29B$270.38M7 Day Performance-5.17%0.41%0.46%2.69%1 Month Performance-1.87%4.23%4.59%5.98%1 Year Performance63.24%9.41%73.41%25.93% Ascendis Pharma A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASNDAscendis Pharma A/S3.1994 of 5 stars$194.62-0.5%$244.36+25.6%+64.0%$11.91B$490.75M-37.721,017Positive NewsTAKTakeda Pharmaceutical2.4572 of 5 stars$15.27-0.9%N/A+2.8%$49.00B$30.09B50.8847,455High Trading VolumeARGXargenex3.9706 of 5 stars$768.00+2.3%$772.84+0.6%+40.6%$45.95B$2.25B39.381,599Analyst DowngradeONCBeOne Medicines1.6955 of 5 stars$346.45+1.4%$330.89-4.5%N/A$37.46B$3.81B-200.2611,000Insider TradeINSMInsmed3.3486 of 5 stars$146.68+1.1%$139.86-4.7%+95.5%$30.67B$363.71M-25.691,271Positive NewsBNTXBioNTech2.5214 of 5 stars$102.66-8.7%$135.80+32.3%-21.6%$27.04B$2.98B-64.166,772High Trading VolumeTEVATeva Pharmaceutical Industries2.9952 of 5 stars$19.30+1.8%$24.71+28.1%+8.4%$21.73B$16.54B-120.6136,830SMMTSummit Therapeutics3.0865 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$19.30BN/A-19.25110Gap DownHigh Trading VolumeGMABGenmab A/S3.9454 of 5 stars$27.54flat$37.60+36.5%+3.4%$17.67B$3.12B13.842,682Positive NewsVTRSViatris1.5976 of 5 stars$10.48-0.2%$10.40-0.8%-14.6%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.2893 of 5 stars$14.27-0.5%$16.95+18.8%-8.9%$11.97B$3.81B21.6127,811News CoveragePositive News Related Companies and Tools Related Companies TAK Competitors ARGX Competitors ONC Competitors INSM Competitors BNTX Competitors TEVA Competitors SMMT Competitors GMAB Competitors VTRS Competitors RDY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASND) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.